The reason for the clinical hold was lack of aggregated safety data for leronlimab across all trials, right? There really haven't been any drug related serious adverse events, have there? Even the recent cardiac events from Brazil Covid trials were consistent with the typical course of severe Covid, and have unknown distribution between placebo versus LL arms.

So, FDA goes by the book, and even throws the book at you sometimes, and we need to get our book in order. HIV drug should be a layup, but who knows. Gotta dot all the Is and cross all the Ts, or whatever.